**Supplementary Table 1: Demographic characteristics and the survival details of all patients.**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Age/sex/smoking status** | **Histology/TNM** | **Pulmonary leision** | **Metastatic sites (except eyes)\*** | **Gene mutation** | **Ocular involvement** | **Size/height of CM** | **Unifocal/multifocal** | **Systemic treatment/response (expect eyes)** | **Local treatment/response (eyes)** | **Two lines treatment/response (eyes)** | **Three lines treatment/response (eyes)** | **Onset with Ocular symptoms** | **Duration of vision improvement/regression (months)** | **OS from the diagnosis of ocular metastasis (months)** |
| Maturu *et al*[1] | 60/Female/N | ADC/T2N2M1b, IV | LLL | Bone | NA | RE | NA | Unifocal | AP + erlotinib/NA | None/SD | Erlotinib+IV-Bev × 4 (1.25 mg)/PR | None/NA | Y | NA | NA |
| Maturu *et al*[1] | 49/Male/N | SCLC T1aN2M1b, IV | RUL | Liver | NA | BE | LE: 15 mm/RE: 2.25–3 mm | LE: multifocal RE: unifocal | EP/NA | IV-Bev × 4 (1.25 mg)/PD | Topotecan + EBRT/NA | None/NA | Y | NA | NA |
| Singh *et al*[2] | 60/Male/N | ADC/T2N0M1, IV | RLL | Pleura | NA | LE | 1.7 mm × 1.1 mm × 1.8 mm | Unifocal | AP/PR | None/CR | None/NA | None/NA | Y | 11 | NA | |
| Singh *et al*[2] | 42/Female/N | LCC/T1N3M1, IV | RLL | Liver, pleura | NA | LE | 14.8 mm × 13.0 mm × 4.1 mm | Unifocal | TP/CR | IV-Bev × 7 (1.25 mg)/PR | None/NA | None/NA | Y | 9 | NA |
| Singh *et al*[2] | 53/Male/15 packs/year | ADC/T2N2M1, IV | LUL | Liver, adrenal gland, bone | NA | RE | 15.0 mm × 14.5 mm × 6.3 mm | Unifocal | AP/PD | IV-Bev × 3 (1.25 mg)/PD | DC + Bev + EBRT (30 Gy/10 f) + IV-Bev × 2/PR | None/NA | Y | NA | 16 |
| Lai *et al*[3] | 73/Male/Y | ADC/IV | RLL | Pleural, brain | NA | LE | 8.5 mm × 7.5 mm × 2.3 mm | Unifocal | Erlotinib/PD | None/PD | Pemetrexed + docetaxel + IV-Bev × 2 (2.5 mg)/PR | None/NA | N | 4 | NA |
| Salah *et al*[4] | 25/Male/4 packs/year | ADC/IV | Left hilar | Subcutaneous, liver, bone | NA | BE | RE: 15 mm  LE: 7.5 mm | Unifocal | DP/PD | EBRT (30 Gy/10 f)/PD | Local and systemic use of glucocorticoids | None/NA | Y | NA | NA |
| Guo *et al*[5] | 62/Female/NA | SCC/T2aN1 | RLL | Brain | NA | LE | NA | Unifocal | Right lower lobe resection and lymph node dissection/unchanged | Observation/PD | GP/CR | None/NA | Y | 16.5 | NA |
| Singh *et al*[6] | 50/Male/NA | ADC/NA | Right hilar | Lung | NA | RE | 4.5–6 mm | Unifocal | GC/NA | None/CR | None/NA | None/NA | Y | NA | NA |
| Makabe *et al*[7] | 69/Female/NA | ADC/NA | LLL | Periaortic lymph node, adrenal gland, pleural | EGFR exon 21 L858R | LE | 10.4 mm × 6.4 mm × 2.6 mm | Unifocal | Gefitinib/PD | None/PD | AC + Bev/CR | None/NA | Y | 16 | 16 |
| Okuma *et al*[8] | 56/Male/56 packs/year | SCLC/cT4N3M1, IV | Left hilar | Lung, brain | NA | RE | 1.5–3 mm | Unifocal | EP/PR | None/PD | Emergency ocular radiation (40 Gy/20 f)/PD | Amrubicin/PD | N | NA | 14 |
| Funazo *et al*[9] | 40/Female/1 pack/year | ADC/NA | LUL | Liver, bone | EML4-ALK (+, 54%) | RE | NA | Unifocal | Alectinib/PR | None/PR | None/NA | None/NA | Y | 9 | NA |
| Okuma *et al*[10] | 30/Female/NA | ADC/NA | LUL | Liver, bone | EML4-ALK (+, 70%) | LE | 7.5 mm | Unifocal | PD-1/NA | None/PD | Alectinib/PR | None/NA | N | 5 | NA |
| Bearz *et al*[11] | 43/Female/NA | ADC/T2aN2M1, IV | RML | Bone | EML4-ALK (+), EGFR wt KRAS(−), | BE | NA | LE: multifocal  RE: unifocal | Crizotinib/PR | Eye Plastic Surgery/PR | Alectinib/SD | None/NA | Y | 22 | NA |
| Rao and Gragoudas[12] | 31/Male/N | ADC/NA, IV | Lung† | Bone | EML4-ALK + EGFR wt | BE | NA | Multifocal | None/NA | PBT/PR | None/NA | None/NA | N | NA | 6 |
| Feng *et al*[13] | 62/Female/N | ADC/NA, IV | LLL | left hilar lymph node | ALK (+, 34%) | BE | NA | Multifocal | AC/PD | Ocular radiation§ (30 Gy/10 f)/PD | Erlotinib/PR | Crizotinib/PR | Y | 13 | NA |
| Jiang *et al*[14] | 44/Male/N | ADC/T2N2M1, IV | LLL | Lung, brain, liver | EML4-ALK+ | LE | 11 mm × 10 mm × 3.9 mm | Unifocal | VP + thoracic radiation (60 Gy/20 f)/PR | Ocular radiation§ (30 Gy/10 f)/PD | Docetaxel + Enucleation/NA | Crizotinib/SD (except eyes) | Y | 18 | ＞20 |
| de la Barquera Cordero and Hidalgo[15] | 50/Female/NA | NSCLC-NOS/NA | Lung† | NA | NA | RE | 8.8 mm × 7.5 mm × 1.74 mm | Unifocal | None/NA | Iv-Bev × 7 (2.5 mg)/CR | None/NA | None/NA | N | 7 | NA |
| Mariachiara *et al*[16] | 54/Female/N | ADC/NA | Lung† | Bone, brain | Exon 19 secondary to EGFR-T790M | LE | NA | Unifocal | Osimertinib/NA | None/CR | None/NA | None/NA | N | 5 | Follow up |
| Daniels *et al*[17] | 43/Male/N | ADC/NA | Lung† | Bone, brain | NA | LE | Height: 3.39 mm | Unifocal | TC/NA | None/PD | TC + Erlotinib/CR | None/NA | Y | 36 | NA |
| Ye *et al*[18] | 48/Female/Y | ADC/NA, IV | Lung† | Bone, brain | NA | RE | 10 mm × 8 mm × 4.8 mm | Unifocal | Erlotinib/NA | None/CR | None/NA | None/NA | Y | 5 | NA |
| Kim *et al*[19] | 57/Female/Y | ADC/NA, IV | Lung† | NA | NA | LE | Temporal superior quadrant: 8.37 mm × 7.56 mm × 2.48 mm; temporal inferior quadrant: 7.52 mm × 6.21 mm × 2.94 mm | Multifocal | Erlotinib/NA | IV-Bev × 3 (2.5 mg)/CR | None/NA | None/NA | N | 2 | Follow up |
| Nair *et al*[20] | 78/Male/N | ADC/T2aN2M1b, IV | Right hilar | Bone | EGFR wt | LE | 3 mm | Multifocal | Erlotinib/PR | None/PR | None/NA | None/NA | Y | ＞12 | NA |
| Shimomura *et al*[21] | 52/Female/Y | ADC/T4N3M1b, IV | RL | Pleura, bone, brain | EGRF exon 19 (delE746-A750, +) | LE | NA | Unifocal | Gefitinib/PR | None/PR | None/NA | None/NA | Y | 5 | NA |
| George *et al*[22] | 42/Female/NA | LCC/NA | RUL | Lung | NA | RE | 12 mm × 12 mm × 6.3 mm | Unifocal | GC + Bev/PR | None/PR | None/NA | None/NA | Y | ≥13.5 | ≥17 |
| D’Antonio *et al*[23] | 34/Female/NA | ADC/NA | RUL | Lung | NA | LE | NA | Unifocal | GP/SD | IV-Bev × 2 (1.25 mg)/PR | None/NA | None/NA | Y | ≥33 | ≥33 |
| Dall’Olio *et al*[24] | 54/Female/NA | ADC/NA | Lung† | Bone, brain | EGFR secondary to T790M | LE | NA | Unifocal | Osimertinib/NA | None/CR | None/NA | None/NA | N | 3.5 | NA |
| Yasui *et al*[25] | 68/Male/N | ADC/cT2N0M1b, IV | RLL | Bone | NA | LE | 9 mm | Unifocal | AC + Bev/SD | IV-Bev × 1 (1.25 mg)/CR | None/NA | None/NA | Y | 2 | 2 |
| Chu and El-Annan[26] | 28/Male/NA | Carcinoid/NA | Lung† | Bone, brain, liver | NA | RE | 10.07 mm × 4.45 mm | Multifocal | None/NA | Ocular radiation (30 Gy)/PD | PDT/PR | None/NA | N | ≥10 | NA |
| Kawakami *et al*[27] | 75/Female/NA | Carcinoid/NA | Breast or lung‡ | NA | NA | BE | RE: 12 mm/LE: 18 mm × 4.8 mm | LE: multifocal  RE: unifocal | observation 15M/NA | None/PD | LE: EBRT (40 Gy)/PR; RE: PDT/PD | None/NA | Y | ≥14 | ≥30 |
| Lu *et al*[28] | 44/Female/N | ADC/NA, IV | LLL | Pleura, liver, bone, armpits, internal breast lymph nodes | ROS1 (CD74-ROS1, +); EGFR, KRAS, ALK (−) | LE | 3 mm | Unifocal | AC + Bev × 6/PR | None/PD | Crizotinib/PR | None/NA | N | 12 | NA |
| Yang *et al*[29] | 26/Male/10 packs/year | ADC/NA | Lung† | Bone | EGFR wt | BE | NA | Unifocal | AP/SD | None/PR | None/NA | None/NA | N | 2.5 | 3 |
| Yang *et al*[29] | 44/Female/N | ADC/NA | MLBL | NA | EGFR wt | LE | NA | Unifocal | AP/PR | None/PR | None/NA | None/NA | Y | 6 | ≥16 |
| Yang *et al*[29] | 60/Male/NA | ADC/NA | RLL | Bone, brain | EGFR exon 18 | BE | NA | Unifocal | AP/NA | None/PR | None/NA | None/NA | N | 0.75 | 2 |
| Yang *et al*[29] | 33/Female/N | ADC/NA | RLL | Lung | EGFR wt | BE | NA | Unifocal | Gefitinib/PD | None/PD | None/NA | None/NA | N | NA | 3 |
| Bandyopadhyay *et al*[30] | 50/Male/NA | ADC/NA | RUL | Lung, adrenal gland, mesenteric lymph node | NA | LE | 15 mm × 13 mm × 5 mm | Unifocal | Chemotherapy/NA | Ocular radiation§/NA | None/NA | None/NA | Y | NA | 9 |
| Sheils *et al*[31] | 50/Male/NA | NSCLC-NOS/NA, IV | Lung† | NA | EML4-ALK+ | LE | 9 mm | Unifocal | Alectinib/PR | None/PR | None/NA | None/NA | N | ＞2 | ＞3 |
| Abdellatief *et al*[32] | 75/Male/N | ADC/NA | LUL | Bone | ALK+ | BE | 0.78 mm × 4.99 mm | Multifocal | Ceritinib/PR | None/PR | None/NA | None/NA | N | 6 | ≥6 |
| Riess *et al*[33] | 36/Male/N | ADC/NA | LUL | Bone, liver | EGFR exon 20 insertion, PIK3CA E542K | RE | NA | Unifocal | AP + Bev/PR | SBRT/PR | None/NA | None/NA | Y | 15 | 29 |
| Riess *et al*[33] | 60/Male/NA | ADC/NA | LL | Lung, pleura, Bone, brain | EGFR exon 21 L858R | RE | NA | Unifocal | AP + Bev/NA | Whole-brain radiation encompassing to involved eye/PR | Erlotinib/PR | None/NA | N | 15+ | NA |
| Riess *et al*[33] | 42/Male/N | ADC/NA | LLL | Bone | ALK+ | LE | NA | Unifocal | AP + Bev/NA | None/PR | Crizotinib/PD | Irinotecan/NA | Y | 16 | 21 |
| Herrag *et al*[34] | 55/Male/30 packs/year | ADC/NA | RUL | Bone, liver | NA | RE | NA | Unifocal | VP/NA | 3D-CRT (20 Gy/5 f)/PD | None/NA | None/NA | Y | 3 | NA |
| Shamim *et al*[35] | 49/Female/N | SCC/NA | Right hilar | Bone, liver, pleura, abdominal cavity | EGFR wt | LE | The bigger: 13 mm × 12 mm × 5 mm; the smaller: 4.5 mm × 4 mm × 1.5 mm | Multifocal | TC/NA | TC/NA | None/NA | None/NA | Y | NA | NA |
| Bhattacharyya *et al*[36] | 54/Male/20 packs/year | SCLC | LUL | NA | NA | RE | Height: 10 mm | Unifocal | EP/NA | IV-Bev ×5 (2.5 mg) + EBRT (30 Gy/10 f)/NA (visual improvement) | None/NA | None/NA | Y | 6 | NA |
| Fenicia *et al*[37] | 36/Female/NA | ADC/NA | Lung† | NA | NA | LE | NA | Multifocal | None/NA | IV-Bev × 2 (1.25 mg)/PR | None/NA | None/NA | N | 9 | Lost follow-up |
| Okuma *et al*[8] | 61/Female/NA | ADC/NA | LLL | NA | NA | RE | NA | Unifocal | None/NA | IV-Bev × 3 (1.25 mg)/PD | EBRT/NA | None/NA | N | NA | NA |
| Kourie *et al*[39] | 67/Female/N | ADC/NA | LUL | NA | NA | LE | 9 mm × 6 mm × 1.5 mm | Unifocal | TC + Bev/SD | None/CR | None/NA | None/NA | Y | 1.5 | NA |
| Ergenc *et al*[40] | 67/Male/NA | ADC/NA | LLL | Lung, pleura, bone | NA | BE | Height: 2 mm | Multifocal | None/NA | Laser + 3D-CRT | None/NA | None/NA | Y | NA | 4 |
| Sharan *et al*[41] | 78/Male/NA | ADC/NA | RLL | Lung, bone | NA | RE | 5.5 mm × 3.2 mm × 1.4 mm | Unifocal | None/NA | EBRT (30 Gy/10 f)/PR | None/NA | None/NA | Y | 2 | NA |
| Namd *et al*[42] | 59/Female/N | ADC/NA, IV | MLBL | Pleura, bone, brain | EGRF wt, EML4-ALK wt | BE | NA | Multifocal | None/NA | Whole-brain radiation encompassing to involved eye (30 Gy/10 f)/NA | None/NA | None/NA | N | NA | 1 |
| Das *et al*[43] | 42/Female/N | ADC/NA | LLL | Lung | EGFR exon19 | RE | NA | Unifocal | AC/PR | EBRT (30 Gy/10 f)/CR | None/NA | None/NA | Y | 12 | 13 |
| Koufakis *et al*[44] | 60/Female/80 packs/year | SCLC/NA | RUL | Bone | NA | RE | NA | Unifocal | Chemotherapy/NA | None/NA | None/NA | None/NA | Y | NA | 3M |
| Chang *et al*[45] | 63/Female/NA | ADC/T2bN2M1b, IV | LUL | Subcutaneous, adrenal gland, bone | NA | BE | Height: 3.2 mm | Multifocal | AP\*6 | None/NA | None/NA | None/NA | Y | 24 | NA |
| Maskell *et al*[46] | 56/Female/NA | ADC/NA | RUL | Bone, brain | EGFR exon19 | LE | NA | Unifocal | Gefitinib/NA | None/CR | None/NA | None/NA | Y | 6 | NA |
| Chen *et al*[47] | 63/Female/NA | ADC/NA | Lung† | Bone, brain | EGFR exon 21 L861Q | LE | Height: 2.9 mm | Unifocal | Erlotinib/NA | None/PR | Whole-brain radiation encompassing to involved eye (35 Gy)/PD | Docetaxel/PR | Y | 24 | NA |
| Cui *et al*[48] | 35/Female/N | ADC/T1aN3M1, IV | LUL | Bone | ALK+ | RE | Height: 4.61 mm | Unifocal | Chemotherapy/NA | None/PD | Crizotinib/PR | Brigatinib/PR | Y | 18.5 | NA |
| Inoue *et al*[49] | 68/Female/NA | ADC/NA | MLBL | NA | NA | BE | NA | RE: multifocal  LE: unifocal | Gefitinib/NA | None/PR | None/NA | None/NA | Y | 3 | NA |

\*Metastasis to mediastinal lymph nodes is not specifically mentioned.

†Uncertain primary lesion.

‡Primary tumors failure to recognize from breast or lung cancer.

§Ocular radiotherapy not otherwise specified.

ADC: Adenocarcinoma; CM: Choroidal metastasis; EBRT: External beam radiation therapy; GC: Gemcitabine plus carboplatin; GP: Gemcitabine plus cisplatin; IV-Bev: Intravitreal bevacizumab; LE: Left eye; LLL: Left lower lobe; LUL: Left upper lobe; MLBL: Multifocal lesions in both lungs; N: No; NA: Not available; NSCLC: Non-small cell lung cancer; NSCLC-NOS: Non-small cell lung cancer-not otherwise specified; OS: Overall survival; PBT: Proton beam therapy; PDT: Photodynamic therapy; RE: Right eye; RLL: Right lower lobe; RML: Right middle lobe; RUL: Right upper lobe; SBRT: Stereotactic body radiation therapy; SCC: Squamous cell carcinoma; SD: Standard deviation; SCLC: Small cell lung cancer; Y: Yes.

**References**

1. Maturu VN, Singh N, Bansal P, Rai Mittal B, Gupta N, Behera D, *et al*. Combination of intravitreal bevacizumab and systemic therapy for choroidal metastases from lung cancer: Report of two cases and a systematic review of literature. Med Oncol 2014;31:901. doi: 10.1007/s12032-014-0901-z.

2. Singh N, Kulkarni P, Aggarwal AN, Mittal BR, Gupta N, Behera D, *et al*. Choroidal metastasis as a presenting manifestation of lung cancer: A report of 3 cases and systematic review of the literature. Medicine (Baltimore) 2012;91:179–194. doi: 10.1097/MD.0b013e3182574a0b.

3. Lai CL, Fan KS, Lee YH, Chen HC, Fan WH. Intravitreal administration of bevacizumab in the treatment of choroidal metastasis in a patient with erlotinib-failed pulmonary adenocarcinoma. Lung Cancer 2012;76:496–498. doi: 10.1016/j.lungcan.2012.02.020.

4. Salah S, Khader J, Yousef Y, Salem A, Al-Hussaini M, Al-Asady R. Choroidal metastasis as the sole initial presentation of metastatic lung cancer. Hematol Oncol Stem Cell Ther 2012;5:60–65. doi: 10.5144/1658-3876.2012.60.

5. Guo Y, Wang X, Xiao J, Xu Y, Cai Y, Sun C, *et al*. Lung squamous cell carcinoma with solitary ocular metastasis and its successful treatment with thoracic surgery and chemotherapy: An interesting and rare case report. BMC Cancer 2018;18:1004. doi: 10.1186/s12885-018-4944-y.

6. Singh A, Singh P, Sahni K, Shukla P, Shukla V, Pant NK. Non-small cell lung cancer presenting with choroidal metastasis as first sign and showing good response to chemotherapy alone: A case report. J Med Case Rep 2010;4:185. doi: 10.1186/1752-1947-4-185.

7. Makabe K, Kurishima K, Shiozawa T, Miyazaki K, Ohara G, Kagohashi K, *et al*. Treatment of choroid metastasis from lung adenocarcinoma with bevacizumab-containing chemotherapy: A case report. Exp Ther Med 2016;11:239–242. doi: 10.3892/etm.2015.2893.

8. Okuma Y, Hosomi Y, Kitamura K, Iguchi M, Okamura T, Fukami S, *et al*. Choroidal metastasis in a patient with small cell lung cancer discovered during treatment with chemotherapy. Int J Clin Oncol 2009;14:541–544. doi: 10.1007/s10147-009-0881-8.

9. Funazo T, Morita K, Ikegami N, Konishi C, Nakao S, Ariyasu R, *et al*. Successful treatment with alectinib for choroidal metastasis in anaplastic lymphoma kinase rearranged non-small cell lung cancer. Intern Med 2017;56:2317–2320. doi: 10.2169/internalmedicine.8488-16.

10. Okuma Y, Tanaka Y, Kamei T, Hosomi Y, Okamura T. Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer. Onco Targets Ther 2015;8:1321–1325. doi: 10.2147/OTT.S83179.

11. Bearz A, Santarossa S, Manfrè A, Beltrame G, Urbani M, Sartor I, *et al*. Activity of crizotinib over choroidal metastases in non-small-cell lung cancer (NSCLC)-ALK rearranged: A case report. BMC Res Notes 2014;7:589. doi: 10.1186/1756-0500-7-589.

12. Rao RC, Gragoudas ES. Choroidal metastases from EML4-ALK-positive non-small-cell lung adenocarcinoma. J Clin Oncol 2015;33:e112–e114. doi: 10.1200/JCO.2013.50.2740.

13. Feng Y, Singh AD, Lanigan C, Tubbs RR, Ma PC. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry. J Thorac Oncol 2013;8:e109–e111. doi: 10.1097/01.JTO.0000437502.82078.9b.

14.Jiang K, Brownstein S, Sekhon HS, Laurie SA, Lam K, Gilberg S, *et al*. Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature. Saudi J Ophthalmol 2013;27:187–192. doi: 10.1016/j.sjopt.2013.06.011.

15. de la Barquera Cordero AS, Hidalgo RAC. Intravitreal bevacizumab for choroidal metastasis of lung carcinoma; A case report. J Ophthalmic Vis Res 2010;5:265–268.

16. Mariachiara M, Celeste R, Federico F, Nicole B, Antonio C. Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: A case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor. Int Ophthalmol 2018;38:2669–2675. doi: 10.1007/s10792-017-0749-2.

17. Daniels AB, Miller ML, Kotecha A, Abramson DH. Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib. Retin Cases Brief Rep 2010;4:390–393. doi: 10.1097/ICB.0b013e3181e180e6.

18. Ye X, Kaliki S, Shields CL. Rapid regression of choroidal metastasis from lung cancer using erlotinib (Tarceva). Oman J Ophthalmol 2014;7:75–77. doi: 10.4103/0974-620X.137159.

19. Kim SW, Kim MJ, Huh K, Oh J. Complete regression of choroidal metastasis secondary to non-small-cell lung cancer with intravitreal bevacizumab and oral erlotinib combination therapy. Ophthalmologica 2009;223:411–413. doi: 10.1159/000229307.

20. Nair AG, Asnani HT, Mehta VC, Mehta SV, Pathak RS, Palkar AH, *et al*. Tyrosine kinase inhibitors in the treatment of choroidal metastases from non-small-cell lung cancer: A case report and review of literature. Ocul Oncol Pathol 2017;3:28–33. doi: 10.1159/000448114.

21. Shimomura I, Tada Y, Miura G, Suzuki T, Matsumura T, Tsushima K, *et al*. Choroidal metastasis of non-small cell lung cancer that responded to gefitinib. Case Rep Ophthalmol Med 2013;2013:213124. doi: 10.1155/2013/213124.

22. George B, Wirostko WJ, Connor TB, Choong NW. Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy. J Thorac Oncol 2009;4:661–662. doi: 10.1097/JTO.0b013e31819c9a73.

23. D’Antonio C, Viterbo A, Romiti A, Enrici MM, Lauro S, Marchetti P. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab. J Thorac Oncol 2012;7:468–469. doi: 10.1097/JTO.0b013e3182398f7b.

24. Dall'Olio FG, Ruatta C, Melotti B, Sperandi F, Ciardella AP, Ardizzoni A. Response to osimertinib in choroidal metastases from EGFRmt T790M-positive non-small cell lung adenocarcinoma. J Thorac Oncol 2017;12:e165–e167. doi: 10.1016/j.jtho.2017.06.001.

25. Yasui H, Sato K, Takeyama Y, Nishihara H, Maeda M, Gonda H, *et al*. Effective treatment with intravitreal injection of bevacizumab for exudative retinal detachment secondary to choroidal metastasis of non-small cell lung carcinoma. Am J Case Rep 2015;16:728–732. doi: 10.12659/ajcr.894600.

26. Chu CK, El-Annan J. Photodynamic therapy for choroidal carcinoid metastasis. Can J Ophthalmol 2018;53:e13–e16. doi: 10.1016/j.jcjo.2017.06.012.

27. Kawakami S, Wakabayashi Y, Goto H. A case of presumed choroidal metastasis from carcinoid tumor treated by photodynamic therapy with verteporfin. Clin Ophthalmol 2013;7:2003–2006. doi: 10.2147/OPTH.S51196.

28. Lu S, Azada MC, Ou SH. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient. Lung Cancer 2015;87:207–209. doi: 10.1016/j.lungcan.2014.12.011.

29. Yang CJ, Tsai YM, Tsai MJ, Chang HL, Huang MS. The effect of chemotherapy with cisplatin and pemetrexed for choroidal metastasis of non-squamous cell carcinoma. Cancer Chemother Pharmacol 2014;73:199–205. doi: 10.1007/s00280-013-2341-4.

30. Bandyopadhyay S, Adrean SD, Puklin JE, Feng J. Choroidal metastasis from an occult primary diagnosed by fine-needle aspiration: A case report. Diagn Cytopathol 2009;37:38–41. doi: 10.1002/dc.20918.

31. Sheils CR, Hartmann AJPW, Kuriyan AE. Visual disturbance in a middle-aged woman with non-small cell lung cancer. JAMA Ophthalmol 2018;136:702–703. doi: 10.1001/jamaophthalmol.2017.5776.

32. Abdellatief A, Molina JR, Pulido JS. Response of uveal metastases to ALK inhibitors in ALK-positive non-small-cell lung cancer. Retin Cases Brief Rep 2016;10:37–40. doi: 10.1097/ICB.0000000000000190.

33. Riess JW, Nagpal S, Das M, Neal JW, Kim JW, Wakelee HA. A case series of NSCLC patients with different molecular characteristics and choroidal metastases: Improvement in vision with treatment including pemetrexed and bevacizumab. J Thorac Oncol 2013;8:e17–e18. doi: 10.1097/JTO.0b013e31827690da.

34. Herrag M, Lahmiti S, Yazidi AA, Le Lez ML, Diot P. Choroidal metastasis revealing a lung adenocarcinoma. Ann Thorac Surg 2010;89:1013–1014. doi: 10.1016/j.athoracsur.2009.09.065.

35. Shamim S, Vidya S, Kabir S, Ghosh B. Choroidal metastases as the initial presentation of lung cancer: A rare scenario. Niger J Clin Pract 2017;20:905–909. doi: 10.4103/1119-3077.212439.

36. Bhattacharyya T, Kapoor R, Bahl A, Yadav BS, Singh U, Joshi K, *et al*. Carcinoma lung presenting with choroidal metastasis as initial presentation: A rarity. J Cancer Res Ther 2013;9:504–506. doi: 10.4103/0973-1482.119361.

37. Fenicia V, Abdolrahimzadeh S, Mannino G, Verrilli S, Balestrieri M, Recupero SM. Intravitreal bevacizumab in the successful management of choroidal metastases secondary to lung and breast cancer unresponsive to systemic therapy: A case series. Eye (Lond) 2014;28:888–891. doi: 10.1038/eye.2014.96.

38. Maudgil A, Sears KS, Rundle PA, Rennie IG, Salvi SM. Failure of intravitreal bevacizumab in the treatment of choroidal metastasis. Eye (Lond) 2015;29:707–711. doi: 10.1038/eye.2015.21.

39. Kourie HR, Antoun J, Schakal A, Nasr E, Sahyoun M, Kattan J. Complete disappearance of choroidal metastasis from lung adenocarcinoma treated with bevacizumab and chemotherapy. Case Rep Ophthalmol Med 2015;2015:142408. doi: 10.1155/2015/142408.

40. Ergenc H, Onmez A, Oymak E, Tanriseven R, Celik E, Onmez FE, *et al*. Bilateral choroidal metastases from lung adenocarcinoma: A case report. Case Rep Oncol 2016;9:530–536. doi: 10.1159/000449154.

41. Sharan K, Shailaja S, Pai VH, Fernandes DJ. Choroidal metastases as the presenting feature of adenocarcinoma of the lung: A case report and an overview of the role of radiotherapy in its management. J Cancer Res Ther 2017;13:1062–1064. doi: 10.4103/0973-1482.176413.

42. Namad T, Wang J, Tilton A, Abdel Karim N. Bilateral choroidal metastasis from non-small cell lung cancer. Case Rep Oncol Med 2014;2014:858265. doi: 10.1155/2014/858265.

43. Das SK, Sahoo TK, Parija S, Majumdar SKD, Parida DK. Choroidal metastasis as initial presentation in adenocarcinoma of lung: A case report. J Clin Diagn Res 2017;11:XD04–XD06. doi: 10.7860/JCDR/2017/22533.9446.

44. Koufakis D, Konstantopoulos D, Koufakis T. An uncommon cause of progressive visual loss in a heavy smoker. Pan Afr Med J 2015;22:47. doi: 10.11604/pamj.2015.22.47.7864.

45. Chang YS, Yeung L, Chang LC, Huang JS, Yeh KY. Choroid metastases revealing primary clear cell adenocarcinoma of the lung effectively treated with cisplatin and pemetrexed: A case report. J Med Case Rep 2013;7:267. doi: 10.1186/1752-1947-7-267.

46.Maskell D, Geropantas K, Kouroupis M, Glenn A, Ajithkumar T. Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: Radiotherapy or TKIs? Can J Ophthalmol 2017;52:e22–e25. doi: 10.1016/j.jcjo.2016.09.010.

47. Chen CJ, McCoy AN, Brahmer J, Handa JT. Emerging treatments for choroidal metastases. Surv Ophthalmol 2011;56:511–521. doi: 10.1016/j.survophthal.2011.05.001.

48. Cui ZH, Zhang Y, Liang LL, Li ZH, Abramova I, Hao Q. Development of a new choroidal metastasis in resistance to crizotinib therapy in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Int J Ophthalmol 2017;10:310–314. doi: 10.18240/ijo.2017.02.21.

49. Inoue M, Watanabe Y, Yamane S, Kobayashi S, Arakawa A, Tsukahara T, *et al*. Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib. Eur J Ophthalmol 2010;20:963–965. doi: 10.1177/112067211002000526.